MiMedx Group Inc (MDXG) : The consensus on MiMedx Group Inc (MDXG) based on 5 analyst recommendation on the company stock is 1.4, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
MiMedx Group Inc (MDXG) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $13 and the lowest price target forecast is $9. The average forecast of all the analysts is $11.6 and the expected standard deviation is $1.52.
For the current week, the company shares have a recommendation consensus of Buy. MiMedx Group Inc (NASDAQ:MDXG): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.38 and $7.30 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.52. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.38, notching a gain of 0.27% for the day. The total traded volume was 831,542 . The stock had closed at $7.36 on the previous day.
In a related news,The director officer (President and COO) of Mimedx Group, Inc., Taylor William Charles sold 29,112 shares at $7.53 on July 28, 2016. The Insider selling transaction had a total value worth of $219,213. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.